Mirabegron - Generic Drug Details

What are the generic sources for mirabegron and what is the scope of freedom to operate?

Mirabegron is the generic ingredient in three branded drugs marketed by Alkem Labs Ltd, Apgdi, Apotex, Ascent Pharms Inc, Lupin Ltd, MSN, Qilu, Sawai Usa, and Zydus Pharms, and is included in twelve NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Mirabegron has sixty-six patent family members in twenty-six countries.

There are nineteen drug master file entries for mirabegron. Eight suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for mirabegron

International Patents:	66
US Patents:	6
Tradenames:	3
Applicants:	9
NDAs:	12
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	8
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	162
Patent Applications:	824
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for mirabegron
What excipients (inactive ingredients) are in mirabegron?	mirabegron excipients list
DailyMed Link:	mirabegron at DailyMed

Recent Clinical Trials for mirabegron

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
VA Office of Research and Development	PHASE4
University of Naples	PHASE3
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation	PHASE4

See all mirabegron clinical trials

Generic filers with tentative approvals for MIRABEGRON

Applicant	Application No.	Strength	Dosage Form
		50MG	TABLET, EXTENDED RELEASE;ORAL
		25MG	TABLET, EXTENDED RELEASE

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for mirabegron

Drug Class	beta3-Adrenergic Agonist
Mechanism of Action	Adrenergic beta3-Agonists Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for mirabegron

G04BD	Drugs for urinary frequency and incontinence
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for MIRABEGRON

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MYRBETRIQ GRANULES	Granules for Extended-release Suspension	mirabegron	8 mg/mL	213801	1	2024-01-12
MYRBETRIQ	Extended-release Tablets	mirabegron	50 mg	202611	6	2016-06-28

US Patents and Regulatory Information for mirabegron

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msn	MIRABEGRON	mirabegron	TABLET, EXTENDED RELEASE;ORAL	218543-002	Nov 4, 2025	AB	RX	No	No
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes	10,842,780*PED				Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes	12,059,409*PED				Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes	12,097,189*PED				Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	AB	RX	Yes	Yes	8,772,315*PED				Y
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	AB	RX	Yes	Yes	11,707,451*PED				Y
Sawai Usa	MIRABEGRON	mirabegron	TABLET, EXTENDED RELEASE;ORAL	209446-001	Dec 27, 2019		DISCN	No	No

Expired US Patents for mirabegron

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	7,750,029
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	6,562,375
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	6,699,503
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	7,750,029
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-001	Jun 28, 2012	6,699,503
Apgdi	MYRBETRIQ	mirabegron	TABLET, EXTENDED RELEASE;ORAL	202611-002	Jun 28, 2012	6,562,375

EU/EMA Drug Approvals for mirabegron

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Astellas Pharma Europe B.V.	Betmiga	mirabegron	EMEA/H/C/002388Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome.	Authorised	no	no	no	2012-12-20

International Patents for mirabegron

Country	Patent Number	Title	Estimated Expiration
Mexico	351855
Portugal	3278801
Cyprus	1113670
China	102170878
Poland	2554168
Slovenia	2216021
South Korea	20110071103

Supplementary Protection Certificates for mirabegron

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1028111	300598	Netherlands		PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220
1559427	33/2013	Austria		PRODUCT NAME: MIRABEGRON ODER DESSEN SALZE; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220
1559427	132013902166933	Italy		PRODUCT NAME: MIRABEGRON(BETMIGA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/809/014, 20121220
1559427	C 2013 020	Romania		PRODUCT NAME: MIRABEGRON SAU O SARE A ACESTUIA(2-(2-AMINO-1,3-TRIAZOL-4-IL)-N-[4-(2-{[(2R)-2-HIDROXI9/014; DATE OF NATIONAL AUTHORISATION: 20121220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/809/001 - EU/1/12/809/014; DATE OF FIRST AUTHORISATION IN EEA: 20121220 -2-FENILETIL]AMINO}ETIL)FENIL]ACETAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/12/809/001 - EU/1/12/80
1559427	CR 2013 00028	Denmark		PRODUCT NAME: MIRABEGRON OR A SALT THEREOF; REG. NO/DATE: EU/1/12/809/001-014 20121220
1559427	C300599	Netherlands		PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220
1028111	C300598	Netherlands		PRODUCT NAME: MIRABEGRON EN ZOUTEN ERVAN; REGISTRATION NO/DATE: EU/1/12/809/001-014 20121220

MIRABEGRON: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What drives mirabegron’s market demand?

Mirabegron is an oral beta-3 adrenergic receptor agonist for overactive bladder (OAB). The demand profile is shaped by (1) OAB prevalence, (2) competitive positioning versus antimuscarinics, and (3) payer and guideline alignment.

OAB market pull

• Epidemiology anchor: OAB affects a large share of the adult population, with incidence rising with age. Treated populations in the US and EU expand as geriatric segments grow.
• Clinical behavior: Mirabegron is positioned for patients who do not tolerate antimuscarinics or in whom anticholinergic side effects (dry mouth, constipation, cognitive concerns) drive discontinuation.

Competitive positioning: why mirabegron holds share

• Mechanism differentiation: As a beta-3 agonist, mirabegron competes on tolerability and adherence rather than “same-class” efficacy.
• Switching pattern in practice: Many OAB formularies support step therapy that allows antimuscarinics or mirabegron based on patient tolerability. This structure often sustains a long-tail of mirabegron use.

Evidence base supporting continued coverage

• The drug has an established RCT and long-term safety record in OAB and remains in major prescribing information and clinical references used by payers and clinicians. The US label frames its indication for OAB with symptoms of urge urinary incontinence, urgency, and frequency. (US FDA label: [1])

How has competition evolved versus antimuscarinics and newer OAB agents?

The OAB space has intensified through:

• OAB antimuscarinics (genericized broadly in many markets): These typically compete on price and historical formulary presence. Generics compress pricing for older agents and shift value focus to tolerability and persistence.
• Third-line and combination strategies: Payers increasingly prefer combinations or switch-based care pathways rather than escalating within a single drug class.
• Other beta-3 agonists: New entrants and label expansions across OAB improve overall class credibility, but mirabegron’s long establishment supports continued formulary penetration.

Financial implication of competition

Pricing pressure in developed markets follows the standard generics-to-brand cycle for OAB therapies:

• Brand endurance: If mirabegron retains protected brand share via physician familiarity and payer contracts, revenue declines remain slower than fully exposed generic-only markets.
• Utilization drift to lower-cost alternatives: As antimuscarinics and other comparators become cheaper, mirabegron’s growth depends more on patient-selection rules and outcome-focused coverage.

What does the revenue trajectory indicate about mirabegron’s financial performance?

Mirabegron has been marketed for years and has faced typical maturation dynamics:

• Revenue growth eventually transitions to market share maintenance rather than expansion.
• In most mature pharma franchises, market penetration slows as formularies saturate and competition intensifies.

However, public, decision-grade revenue and financial trajectory figures are not included in the available source set in this response. Under the operating constraints for a complete and accurate market-financial analysis, no numeric revenue trajectory can be reliably produced here.

Where is mirabegron’s financial exposure concentrated (market and lifecycle)?

Mirabegron’s commercial exposure is structurally concentrated in:

• OAB treatment algorithms in the US and EU where oral meds dominate early lines.
• Chronic-use adherence: OAB is persistent for many patients, supporting ongoing refill demand even as incident cases mature.

Its principal risk factors for financial trajectory are typical:

• Formulary changes driven by budget impact.
• Patent-expiry and pricing resets across regions.
• Therapeutic substitution within OAB mechanisms.

What regulatory and labeling factors affect uptake and reimbursement?

US labeling and safety constraints

The US prescribing information for mirabegron includes key clinical and safety positioning that directly affects payer and prescriber confidence:

• Indication: Mirabegron is indicated for OAB patients with symptoms of urge urinary incontinence, urgency, and frequency. (US FDA label: [1])
• Blood pressure considerations: The US label includes hypertension-related warnings/precautions that influence patient selection and monitoring requirements. (US FDA label: [1])
• Renal/hepatic dosing limits: These affect utilization in comorbidity-heavy populations. (US FDA label: [1])

UK and Europe coverage logic

In the UK, mirabegron is incorporated into OAB prescribing approaches as a standard oral option, with uptake tied to:

• stepwise management,
• comorbidity considerations,
• and tolerance profiles.

The UK clinical pathway materials and professional prescribing resources reflect ongoing use of mirabegron for OAB. (NICE/OAB-related resources and UK professional guidance: [2])

What are the near-term commercial levers that shape earnings?

Formulary mechanics and persistence

For chronic conditions like OAB, “earnings” are mostly persistence-driven:

• If payers preserve mirabegron as a covered alternative to antimuscarinics for intolerance, continuation rates stay higher.
• If formularies narrow to cost-led antimuscarinics, mirabegron’s utilization declines.

Sequence of therapy and patient selection

Mirabegron often benefits from:

• patients at risk for anticholinergic adverse effects,
• and those who have previously discontinued antimuscarinics.

Price and contract dynamics

In mature segments:

• Discount intensity and rebates often matter more than list price.
• Budget impact models prioritize acquisition cost and expected discontinuation costs.

What is the patent and exclusivity posture relevant to financial trajectory?

The available source set does not contain a complete, jurisdiction-by-jurisdiction patent expiry map for mirabegron that would support a rigorous earnings-at-risk assessment. Without that, no defensible patent-driven forecast can be produced under the constraints.

The sources provided support basic regulatory and clinical context but do not supply the necessary patent and exclusivity details to model financial trajectory impacts.

What is the net assessment of mirabegron’s financial trajectory given the evidence available here?

Based on the regulatory and clinical foundation, mirabegron’s financial trajectory follows a mature brand pattern:

• stable utilization anchored by OAB prevalence,
• competitive pressure from antimuscarinics (especially generics),
• and value retention through tolerability and patient-selection criteria.

No numeric revenue trajectory can be stated without decision-grade financial data in the cited sources.

---

Key Takeaways

• Mirabegron demand is driven by OAB prevalence and patient selection where antimuscarinic tolerability becomes the decision point.
• Competition compresses pricing but does not eliminate utility because switching behavior and step therapy sustain a baseline patient flow.
• Regulatory labeling materially affects uptake via hypertension precautions and dosing limits, which shape prescribing and reimbursement rules.
• A numeric financial trajectory is not supported by the available cited sources in this response set.

---

FAQs

1. What is mirabegron approved to treat?
   Overactive bladder symptoms including urge urinary incontinence, urgency, and frequency. [1]

2. Why does mirabegron compete against antimuscarinics?
   It has a distinct beta-3 adrenergic mechanism and is chosen when antimuscarinic side effects limit adherence. [1]

3. What label constraints can affect patient access?
   Hypertension precautions and renal/hepatic dosing limitations affect eligibility and monitoring. [1]

4. Is mirabegron used in stepwise OAB care in the UK?
   Yes. UK professional prescribing resources include mirabegron within ongoing OAB management pathways. [2]

5. Can this analysis provide a numeric revenue forecast?
   Not from the cited sources provided here.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Myrbetriq (mirabegron) prescribing information. https://www.accessdata.fda.gov
[2] National Health Service / UK professional resources. (n.d.). Overactive bladder guidance and prescribing references including mirabegron. https://www.nhs.uk